Evidence map›Paper›PMID 40549200›Full record

ReviewZeitschrift fur Gerontologie und Geriatrie2025

[Androgen deprivation therapy of prostate cancer from a geriatric perspective].

A Wiedemann, K Becher, A Manseck, J Stein, M Fröhner, C Fiebig, A Piotrowski, R Kirschner-Hermanns, A Bannowsky, S Wirz and 2 more

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Gerontologie und Geriatrie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

A WiedemannUrologische Klinik, Lehrstuhl für Geriatrie, Universität Witten/Herdecke, Evangelisches Krankenhaus Witten gGmbH, Pferdebachstr. 27, 58455, Witten, Deutschland. awiedemann@evk-witten.de.
K BecherKlinik für allgemeine und geriatrische Rehabilitation Wartenberg, Wartenberg, Deutschland.
A ManseckUrologische Abteilung, Klinikum Ingolstadt, Ingolstadt, Deutschland.
J SteinUrologische Abteilung, Klinikum Großburgwedel, Großburgwedel, Deutschland.
M FröhnerKlinik für Urologie, Zeisigwaldkliniken Bethanien Chemnitz, Chemnitz, Deutschland.
C FiebigUrologische und Kinderurologische Klinik, Uniklinikum Erlangen, Erlangen, Deutschland.
A PiotrowskiKlinik für Urologie und Kinderurologie, Klinikum Bad Hersfeld, Bad Hersfeld, Deutschland.
R Kirschner-HermannsNeuro-Urologie, Neurologisches Rehabilitationszentrum Johanniterkliniken Godeshöhe Bonn, Bonn, Deutschland.
A BannowskyKliniken Landkreis Diepholz, Urologische Klinik, Diepholz, Deutschland.
S WirzAbteilung für Anästhesiologie, Intensivmedizin, Schmerz- und Palliativmedizin, Zentrum für Schmerzmedizin, Weaningzentrum, GFO-Kliniken Bonn/Cura Bad Honnef, Bad Honnef, Deutschland.
J SalemAbteilung für Urologie, Klinik Links vom Rhein, Curos urologisches Zentrum Köln, Köln, Deutschland.
T H KuruAbteilung für Urologie, Klinik Links vom Rhein, Curos urologisches Zentrum Köln, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) for prostate cancer is carried out in a palliative approach in symptomatic geriatric patients. Testosterone synthesis is suppressed using a dual therapy principle with luteinising hormone-releasing hormone (LH-RH) analogues or antagonists of LH-RH, in addition to modern antiandrogens. Additional administration of taxanes is initially possible in cases of high tumor burden and aggressive tumor biology, which is otherwise reserved for castration-resistant prostate cancer. The ADT is a systemic therapy for all testosterone-dependent processes and can lead to hot flushes, gynecomastia, osteoporosis, sarcopenia, anemia, falls, cognitive decline, depression, metabolic syndrome, increased cardiovascular events and many drug interactions. In patients identified as geriatric, ADT should therefore only be used after a thorough risk-benefit analysis.

Indexed as

Androgen AntagonistsPalliative CareProstatic NeoplasmsAgedAged, 80 and overEvidence-Based MedicineHumansMaleTreatment OutcomeAndrogen AntagonistsCastration-resistant prostatic neoplasmCombination drug therapyGeriatric assessmentGeriatric urologyGonadotropin-releasing hormone analoguesLuteinising hormone-releasing hormone analogues

Identifiers

PMID40549200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.